Identifying FGA peptides as nasopharyngeal carcinoma-associated biomarkers by magnetic beads

Journal of Cellular Biochemistry

Volumn 113, Issue 7, 2012, Pages 2268-2278

  Tao, Ya Lan ^a   Li, Yan ^a,b   Gao, Jin ^a   Liu, Zhi Gang ^a   Tu, Zi Wei ^a   Li, Guo ^a   Xu, Bing Qing ^a   Niu, Dao Li ^c   Jiang, Chang Bin ^c   Yi, Wei ^c   Li, Zhi Qiang ^d   Li, Jing ^d   Wang, Yi Ming ^e   Cheng, Zhi Bin ^f   Liu, Qiao Dan ^f   Bai, Li ^g   Zhang, Chun ^h   Zhang, Jing Yu ^h   Zeng, Mu Sheng ^a   Xia, Yun Fei ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Bioyong (Beijing) Technology Co Ltd   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

^d GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^e JINAN UNIVERSITY   (China)

^f SUN YAT SEN UNIVERSITY   (China)

^g HUIZHOU MUNICIPAL CENTRAL HOSPITAL   (China)

^h DONGGUAN PEOPLE'S HOSPITAL   (China)

Author keywords

fga; magnetic bead; nasopharyngeal carcinoma; Serum biomarker

Indexed keywords

FIBRINOGEN; FIBRINOGEN A ALPHA CHAIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ACCURACY; ADULT; ALGORITHM; AMINO ACID SEQUENCE; ARTICLE; CANCER PROGNOSIS; CATION EXCHANGE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; EARLY DIAGNOSIS; FEMALE; HUMAN; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN PURIFICATION; PROTEOMICS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; WEAK CATIONIC EXCHANGER MAGNETIC BEAD;

ADULT; AMINO ACID SEQUENCE; FEMALE; FIBRINOGEN; HUMANS; MAGNETIC PHENOMENA; MAGNETITE NANOPARTICLES; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PEPTIDES; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84861057905     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24097     Document Type: Article

References (41)

1. Cai MY, Tong ZT, Zhu W, Wen ZZ, Rao HL, Kong LL, Guan XY, Kung HF, Zeng YX, Xie D,. 2011. H3K27me3 protein is a promising predictive biomarker of patients' survival and chemoradioresistance in human nasopharyngeal carcinoma. Mol Med [Epub ahead of print]. DOI: 10.2119/molmed.2011.00054
2. Chang KP, Chang YT, Wu CC, Liu YL, Chen MC, Tsang NM, Hsu CL, Chang YS, Yu JS,. 2011. Multiplexed immunobead-based profiling of cytokine markers for detection of nasopharyngeal carcinoma and prognosis of patient survival. Head Neck 33: 886-897.
3. Chen YD, Zheng S, Yu JK, Hu X,. 2004. Artificial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clin Cancer Res 10: 8380-8385.
4. Chen Y, Liu MZ, Liang SB, Zong JF, Mao YP, Tang LL, Guo Y, Lin AH, Zeng XF, Ma J,. 2008. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys 71: 1356-1364.
5. Cheng AJ, Chen LC, Chien KY, Chen YJ, Chang JT, Wang HM, Liao CT, Chen IH,. 2005. Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin Chem 51: 2236-2244.
6. Cho WC, Yip TT, Yip C, Yip V, Thulasiraman V, Ngan RK, Lau WH, Au JS, Law SC, Cheng WW, Ma VW, Lim CK,. 2004. Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 10: 43-52.
7. Doustjalali SR, Yusof R, Govindasamy GK, Bustam AZ, Pillay B, Hashim OH,. 2006. Patients with nasopharyngeal carcinoma demonstrate enhanced serum and tissue ceruloplasmin expression. J Med Invest 53: 20-28.
8. Feng XP, Yi H, Li MY, Li XH, Yi B, Zhang PF, Li C, Peng F, Tang CE, Li JL, Chen ZC, Xiao ZQ,. 2010. Identification of biomarkers for predicting nasopharyngeal carcinoma response to radiotherapy by proteomics. Cancer Res 70: 3450-3462.
9. Gao J, Hu JY, Xia YF, Yi W, Tao YL, Li G,. 2010. Continuous fall in hemoglobin level is a poor prognostic factor in patients with nasopharyngeal carcinoma treated with radiotherapy. Chin J Cancer 29: 561-566.
10. Ho DW, Yang ZF, Wong BY, Kwong DL, Sham JS, Wei WI, Yuen AP,. 2006. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry serum protein profiling to identify nasopharyngeal carcinoma. Cancer 107: 99-107.
11. Huang YJ, Xuan C, Zhang BB, Liao M, Deng KF, He M, Zhao JM,. 2009. SELDI-TOF MS profiling of serum for detection of nasopharyngeal carcinoma. J Exp Clin Cancer Res 28: 85.
12. Issaq HJ, Conrads TP, Prieto DA, Tirumalai R, Veenstra TD,. 2003. SELDI-TOF MS for diagnostic proteomics. Anal Chem 75: 148A-155A.
13. Jeffries NO,. 2004. Performance of a genetic algorithm for mass spectrometry proteomics. BMC Bioinformatics 5: 180.
14. Lee AW, Sze WM, Au JS, Leung SF, Leung TW, Chua DT, Zee BC, Law SC, Teo PM, Tung SY, Kwong DL, Lau WH,. 2005. Treatment results for nasopharyngeal carcinoma in the modern era: The Hong Kong experience. Int J Radiat Oncol Biol Phys 61: 1107-1116.
15. Li ZQ, Xia YF, Liu Q, Yi W, Liu XF, Han F, Luo W, Lu TX,. 2006. Radiotherapy-related typing in 842 patients in canton with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 66: 1011-1016.
16. Li F, Guan Y, Chen Z,. 2008. Proteomics in nasopharyngeal carcinoma. Cell Mol Life Sci 65: 1007-1012.
17. Lo YM, Chan AT, Chan LY, Leung SF, Lam CW, Huang DP, Johnson PJ,. 2000. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res 60: 6878-6881.
18. Mo L, Wang H, Huang G, Zhao H, Kuang G,. 2005. [Correlation between expression of the Tiam1 gene and the invasion and metastasis in nasopharyngeal carcinoma]. Lin Chuang Er Bi Yan Hou Ke Za Zhi 19: 785-787.
19. Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, Bugge TH,. 2000. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 96: 3302-3309.
20. Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL,. 2002. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 62: 6966-6972.
21. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA,. 2002. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359: 572-577.
22. Powell K,. 2003. Proteomics delivers on promise of cancer biomarkers. Nat Med 9: 980.
23. Preston T, Slater C, McMillan DC, Falconer JS, Shenkin A, Fearon KC,. 1998. Fibrinogen synthesis is elevated in fasting cancer patients with an acute phase response. J Nutr 128: 1355-1360.
24. Seliger B, Kellner R,. 2002. Design of proteome-based studies in combination with serology for the identification of biomarkers and novel targets. Proteomics 2: 1641-1651.
25. Shiwa M, Nishimura Y, Wakatabe R, Fukawa A, Arikuni H, Ota H, Kato Y, Yamori T,. 2003. Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform. Biochem Biophys Res Commun 309: 18-25.
26. Tai HC, Huang HY, Lee SW, Lin CY, Sheu MJ, Chang SL, Wu LC, Shiue YL, Wu WR, Lin CM, Li CF,. 2012. Associations of Rsf-1 overexpression with poor therapeutic response and worse survival in patients with nasopharyngeal carcinoma. J Clin Pathol 65: 248-253.
27. Takeuchi H, Ikeuchi S, Kitagawa Y, Shimada A, Oishi T, Isobe Y, Kubochi K, Kitajima M, Matsumoto S,. 2007. Pretreatment plasma fibrinogen level correlates with tumor progression and metastasis in patients with squamous cell carcinoma of the esophagus. J Gastroenterol Hepatol 22: 2222-2227.
28. Tao YL, Liu ZG, Xia YF, Yi W,. 2011. [Establishment of a specific serum proteomic profile model of nasopharyngeal carcinoma by MALDI-TOF MS]. Zhonghua Zhong Liu Za Zhi 33: 188-191.
29. Verheul HM, van Erp K, Homs MY, Yoon GS, van der Groep P, Rogers C, Hansel DE, Netto GJ, Pili R,. 2010. The relationship of vascular endothelial growth factor and coagulation factor (fibrin and fibrinogen) expression in clear cell renal cell carcinoma. Urology 75: 608-614.
30. Villanueva J, Martorella AJ, Lawlor K, Philip J, Fleisher M, Robbins RJ, Tempst P,. 2006a. Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol Cell Proteomics 5: 1840-1852.
31. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P,. 2006b. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116: 271-284.
32. Wei YS, Zheng YH, Liang WB, Zhang JZ, Yang ZH, Lv ML, Jia J, Zhang L,. 2008. Identification of serum biomarkers for nasopharyngeal carcinoma by proteomic analysis. Cancer 112: 544-551.
33. Wellmann A, Wollscheid V, Lu H, Ma ZL, Albers P, Schutze K, Rohde V, Behrens P, Dreschers S, Ko Y, Wernert N,. 2002. Analysis of microdissected prostate tissue with ProteinChip arraysâ€"A way to new insights into carcinogenesis and to diagnostic tools. Int J Mol Med 9: 341-347.
34. Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, Ward RL, Hawkins NJ, Quinn DI, Russell PJ, Sutherland RL, Breit SN, Moskaluk CA, Frierson HF Jr, Hampton GM,. 2003. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci USA 100: 3410-3415.
35. Wu CC, Chien KY, Tsang NM, Chang KP, Hao SP, Tsao CH, Chang YS, Yu JS,. 2005. Cancer cell-secreted proteomes as a basis for searching potential tumor markers: Nasopharyngeal carcinoma as a model. Proteomics 5: 3173-3182.
36. Wu P, Zhang H, Qi L, Tang Q, Tang Y, Xie Z, Lv Y, Zhao S, Jiang W,. 2012. Identification of ERp29 as a biomarker for predicting nasopharyngeal. Oncol Rep 27: 987-994.
37. Xiao Z, Adam BL, Cazares LH, Clements MA, Davis JW, Schellhammer PF, Dalmasso EA, Wright GL Jr., 2001. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res 61: 6029-6033.
38. Xiao ZQ, Chen Y, Yi B, Li MY, Zhang PF, Yi H, Duan CJ, Li C, Li JL, Tang CE, Yang F, Zhu GQ, Chen ZC,. 2007. Identification of nasopharyngeal carcinoma antigens that induce humoral immune response by proteomic analysis. Proteomics Clin Appl 1: 688-698.
39. Zeng GQ, Yi H, Li XH, Shi HY, Li C, Li MY, Zhang PF, Feng XP, Wan XX, Qu JQ, Xu Y, Sun Y, Chen ZC, Xiao ZQ,. 2011. Identification of the proteins related to p53-mediated radioresponse in nasopharyngeal carcinoma by proteomic analysis. J Proteomics 74: 2723-2733.
40. Zheng Y, Xu Y, Ye B, Lei J, Weinstein MH, O'Leary MP, Richie JP, Mok SC, Liu BC,. 2003. Prostate carcinoma tissue proteomics for biomarker discovery. Cancer 98: 2576-2582.
41. Zou J, Sun Q, Akiba S, Yuan Y, Zha Y, Tao Z, Wei L, Sugahara T,. 2000. A case-control study of nasopharyngeal carcinoma in the high background radiation areas of Yangjiang, China. J Radiat Res (Tokyo) 41 Suppl: 53-62.